DAVIS SELECTED ADVISERS — CVS HEALTH CORP CVS: Quarterly 13F Position History
DAVIS SELECTED ADVISERS has reported CVS HEALTH CORP (CVS) on 30 13F-HR filings in Pactolio's tracked window, first appearing in Q4 2018. As of Q1 2026, the position is sized at 12,239,666 shares ($879.1M market value, 4.04% of the equity book). Quarter-over-quarter share count change: 520,845 (-4.1%) .
- 12,239,666Shares Held (Latest Filing)
- $879.1MReported Market Value (Latest Filing)
- 4.04%Portfolio Weight (% of 13F Equity Book)
- 520,845Quarter-over-Quarter Share Change
- -$133.6MQuarter-over-Quarter Value Change
- 12,760,511Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 30 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 12,239,666 | 520,845 | -4.1% | $879.1M | 4.04% | $71.82 |
| Q4 2025 | 12,760,511 | +1,356,870 | +11.9% | $1.01B | 4.55% | $79.36 |
| Q3 2025 | 11,403,641 | 183,149 | -1.6% | $859.7M | 4.49% | $75.39 |
| Q2 2025 | 11,586,790 | +37,733 | +0.3% | $799.3M | 4.27% | $68.98 |
| Q1 2025 | 11,549,057 | +163,107 | +1.4% | $782.4M | 4.51% | $67.75 |
| Q4 2024 | 11,385,950 | +11,018,438 | +2998.1% | $511.1M | 2.97% | $44.89 |
| Q3 2024 | 367,512 | +2,730 | +0.7% | $23.1M | 0.13% | $62.88 |
| Q2 2024 | 364,782 | +192,039 | +111.2% | $21.5M | 0.13% | $59.06 |
| Q1 2024 | 172,743 | 33,671 | -16.3% | $13.8M | 0.08% | $79.76 |
| Q4 2023 | 206,414 | +1,782 | +0.9% | $16.3M | 0.09% | $78.96 |
| Q3 2023 | 204,632 | 3,177 | -1.5% | $14.3M | 0.09% | $69.82 |
| Q2 2023 | 207,809 | 137 | -0.1% | $14.4M | 0.09% | $69.13 |
| Q1 2023 | 207,946 | 144 | -0.1% | $15.5M | 0.10% | $74.31 |
| Q4 2022 | 208,090 | +722 | +0.3% | $19.4M | 0.13% | $93.19 |
| Q3 2022 | 207,368 | 904 | -0.4% | $19.8M | 0.14% | $95.37 |
| Q2 2022 | 208,272 | 152 | -0.1% | $19.3M | 0.12% | $92.66 |
| Q1 2022 | 208,424 | 5,309 | -2.5% | $21.1M | 0.11% | $101.21 |
| Q4 2021 | 213,733 | 565,467 | -72.6% | $22.0M | 0.10% | $103.16 |
| Q3 2021 | 779,200 | 1,226 | -0.2% | $66.1M | 0.31% | $84.86 |
| Q2 2021 | 780,426 | 853 | -0.1% | $65.1M | 0.27% | $83.44 |
| Q1 2021 | 781,279 | 10,120 | -1.3% | $58.8M | 0.26% | $75.23 |
| Q4 2020 | 791,399 | 6,796 | -0.9% | $54.1M | 0.26% | $68.30 |
| Q3 2020 | 798,195 | 14,422 | -1.8% | $46.6M | 0.26% | $58.40 |
| Q2 2020 | 812,617 | +7,998 | +1.0% | $52.8M | 0.31% | $64.97 |
| Q1 2020 | 804,619 | 7,689 | -0.9% | $47.7M | 0.32% | $59.33 |
| Q4 2019 | 812,308 | 253,227 | -23.8% | $60.3M | 0.29% | $74.29 |
| Q3 2019 | 1,065,535 | 36,147 | -3.3% | $67.2M | 0.34% | $63.07 |
| Q2 2019 | 1,101,682 | 22,557 | -2.0% | $60.0M | 0.30% | $54.49 |
| Q1 2019 | 1,124,239 | 5,820 | -0.5% | $60.6M | 0.30% | $53.93 |
| Q4 2018 | 1,130,059 | — | — | $74.0M | 0.41% | $65.51 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did DAVIS SELECTED ADVISERS first disclose a CVS position in 13F-HR filings?
DAVIS SELECTED ADVISERS first reported CVS HEALTH CORP (CVS) on its 13F-HR filing for the period ending 2018-12-31 (Q4 2018). The position has appeared on 30 reported quarters within Pactolio's tracked window.
What was DAVIS SELECTED ADVISERS's most recent quarter-over-quarter share-count change in CVS?
Between Q4 2025 and Q1 2026, DAVIS SELECTED ADVISERS reduced its CVS position by 520,845 shares (-4.1%), leaving 12,239,666 shares at a market value of $879.1M.
Does the implied price-per-share represent DAVIS SELECTED ADVISERS's cost basis in CVS?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.